Scar PreventionPhase 2NCT00892723
A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars
A Phase 2 study testing AZX100 Drug Product in people with Scar Prevention and Scar Reduction, run by Capstone Therapeutics at 3 sites in United States.
Trial summary
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Scar Prevention, Scar Reduction
- What is being tested?
- AZX100 Drug Product
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 59 participants
- Where
- 3 sitesUnited States
- Study dates
- May 2009to Sep 2010
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Keloid scar located below the neck between 1 and 3 cm long and less than 1 cm at its widest point
- Willing to undergo keloid scar excision surgery
- Healthy adult male or non-pregnant female
- Non-diabetic
- Body Mass Index in the range of 18-35
- No clinically significant abnormal values on a full blood safety screen
- Non-smoker and non-nicotine user for the previous six months
Who cannot join
- History or clinical evidence of acute or chronic disease
- History of cancer within the last 5 years, except for surgically removed cancers of the skin that are not near the keloid area
- History of anaphylactic shock or anaphylactoid (hypersensitivity) reaction
- Allergy to local anesthesia, including lidocaine and epinephrine
- Dermatologic disorders, except for folliculitis and acne
- On therapy with steroids
Show all 19Show fewer
- On therapy with a drug that would affect collagen synthesis
- Positive urine test for nicotine or drugs of abuse
- Positive blood test for HIV 1 or 2, hepatitis B or hepatitis C
- Positive blood test for anti-AZX100 antibodies
- Participation in another study within 60 days prior to enrollment
- Blood donation within 7 days before dosing with study drug
- Plasma donation within 3 days before dosing with study drug
- Tattoo within approximately 3 cm of the keloid scar that will be removed
- Apply any lotion or cream on or near the keloid scar that will be removed within 14 days before dosing with study drug
- Use of a tanning bed or tanning light within the 3 months before enrollment
- Intend to use any scar improving product during of the study (1 year)
- History of drug addiction or excessive use of alcohol
- Previous drug treatment of the keloid scar within the last 3 years, or have had any laser, irradiation, or surgical treatment of the keloid scar that will be removed
Trial locations and contacts
3 sites in 1 country.
United States3 sites
DermResearch, Inc.
Austin, Texas, 78759
Lotus Clinical Research, Inc.
Pasadena, California, 91105
Paddington Testing Company, Inc.
Philadelphia, Pennsylvania, 19103
About this study
Official title: A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
- Conditions
- Scar Prevention, Scar Reduction
- Being tested
- AZX100 Drug Product, Placebo
- Keywords
- AZX100, Patient and Observer Scar Assessment Scale, POSAS, Visual Analog Scale, VAS, Keloid, Scarring, Scar reduction, Scar prevention
- Medical subject headings
- Keloid, Cicatrix
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZX100 Drug ProductDrug
Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
PlaceboDrug
Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
AZX100 Drug ProductDrug
Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
| Study group | Role | What they receive |
|---|---|---|
| Low Dose | Experimental | Not described Receives: Drug: AZX100 Drug Product |
| High Dose | Experimental | Not described Receives: Drug: AZX100 Drug Product |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores
Efficacy was based on the difference between mean POSAS scores of placebo, 0.3 mg AZX100, and 1 mg AZX100 12 months after surgery. This gave four comparisons to placebo: patient or observer and 0.3 mg and 1 mg AZX100. PSAS included patients' ratings on a scale of 1-10 (1 was normal skin or no complaints and 10 was the worst imaginable scar or the worst difference) for the following: Is the scar painful? Is the scar itching? Is the color of the scar different? Is the scar more stiff? Is the thickness of the scar different? Is the scar irregular? The possible minimum score was 6 and the maximum (worst) score was 60. OSAS included observers' ratings on a scale of 1-10 (1 was normal skin and 10 was the worst scar imaginable) for vascularization, pigmentation, thickness, relief, and pliability. The possible minimum score was 5 and the possible maximum (worst) score was 50.
Measured: 12 Months
Secondary outcomes (3)
Between-group Mean Differences in Visual Analog Scale (VAS) Scores by Independent Blinded Raters
At 12 months, two independent dermatologists who were blinded to study treatment evaluated the scar images using a Visual Analog Scale (VAS) of 0-100 mm, with 0 being normal skin and 100 being the worst scar imaginable. The scars were presented in a scrambled order. Efficacy was based on the difference between VAS scores of placebo and 0.3 mg AZX100, and placebo and 1 mg AZX100, for each of the two raters separately. Data from the two raters was not combined.
Measured: 12 Months
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Elevation, Length, Width)
This secondary outcome included measurements based on 3D photography of the scar surface at Month 12 and included maximum length, maximum width perpendicular to the maximum length, and minimum, maximum and mean elevation. All elevation measurements were made relative to the interpolated smooth skin surface. A value closest to zero was preferred, because zero was equal to the normal skin surface. The minimum elevation value was calculated as the lowest point of the scar below the interpolated smoooth skin surface and was always a negative number. A more negative number was worse, because it indicated a deeper measurement below the interpolated smooth skin surface. The maximum elevation value was calculated as the highest point of the scar above the interpolated smooth skin surface. A larger number was worse because it indicated a higher peak above the interpolated smooth skin surface. The mean elevation of the scar relative to the interpolated smooth skin surface was also calculated.
Measured: 12 Months
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Volume)
This secondary outcome included measurements based on 3D photography of the scar surface at Month 12 and included positive volume, negative volume and total volume. All volume measurements were made relative to the interpolated smooth skin surface. A value closer to zero was preferred, because zero was equal to the normal skin surface. Positive volume was calculated as the volume of the scar above the interpolated smooth skin surface. Negative volume was calculated as the volume of the scar below the interpolated smooth skin surface, and was always a negative number. Total volume was calculated as the sum of the positive volume and the absolute value of the negative volume.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2009 (estimated)
- Study startMay 2009
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Scar PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Capstone Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00892723
- Sponsor's protocol ID
- OL-ASCAR-05
- Status last verified
- Sep 2012
- First submitted
- 30 Apr 2009
- Last updated
- 11 Oct 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Oct 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids
- ClinicalTrials.gov ID
- NCT00892723
- Acronym / sponsor ID
- OL-ASCAR-05
- Conditions
- Scar Prevention, Scar Reduction
- Keywords
- AZX100, Patient and Observer Scar Assessment Scale, POSAS, Visual Analog Scale, VAS, Keloid, Scarring, Scar reduction
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Capstone TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- May 2009
- Primary completion
- Sep 2010 (actual)
- Study completion
- Sep 2010 (actual)
- First posted
- 4 May 2009 (estimated)
- Results
- Posted 11 Oct 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Low Dose | Experimental | Drug: AZX100 Drug Product |
| High Dose | Experimental | Drug: AZX100 Drug Product |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Keloid scar located below the neck between 1 and 3 cm long and less than 1 cm at its widest point
- Willing to undergo keloid scar excision surgery
- Healthy adult male or non-pregnant female
- Non-diabetic
- Body Mass Index in the range of 18-35
Key exclusion criteria (19 listed)
- History or clinical evidence of acute or chronic disease
- History of cancer within the last 5 years, except for surgically removed cancers of the skin that are not near the keloid area
- History of anaphylactic shock or anaphylactoid (hypersensitivity) reaction
- Allergy to local anesthesia, including lidocaine and epinephrine
- Dermatologic disorders, except for folliculitis and acne
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZX100 Drug ProductSubjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery. | Drug | Low Dose |
| PlaceboSubjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery. | Drug | Placebo |
| AZX100 Drug ProductSubjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery. | Drug | High Dose |
Primary outcome
Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores
Time frame: 12 Months
Efficacy was based on the difference between mean POSAS scores of placebo, 0.3 mg AZX100, and 1 mg AZX100 12 months after surgery. This gave four comparisons to placebo: patient or observer and 0.3 mg and 1 mg AZX100. PSAS included patients' ratings on a scale of 1-10 (1 was normal skin or no complaints and 10 was the worst imaginable scar or the worst difference) for the following: Is the scar painful? Is the scar itching? Is the color of the scar different? Is the scar more stiff? Is the thickness of the scar different? Is the scar irregular? The possible minimum score was 6 and the maximum (worst) score was 60. OSAS included observers' ratings on a scale of 1-10 (1 was normal skin and 10 was the worst scar imaginable) for vascularization, pigmentation, thickness, relief, and pliability. The possible minimum score was 5 and the possible maximum (worst) score was 50.
3 secondary outcomes
Between-group Mean Differences in Visual Analog Scale (VAS) Scores by Independent Blinded Raters
Time frame: 12 Months
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Elevation, Length, Width)
Time frame: 12 Months
Between-group Mean Differences in Objective Measures Obtained Via 3D Photography (Volume)
Time frame: 12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Oct 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Scar Prevention
RecruitingPhase 2
SCARFREE-001: Verteporfin for Scar Prevention
Surgical Scar
RecruitingPhase 2
Cleft Lip Scarring After Botox
Cleft Lip, Cleft Lip Scar
Not yet recruitingPhase 1/2
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
Keloid
Active, not recruitingPhase 2/3
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
Scar, Hypertrophic Scar
Recruiting
Efficacy in Preventing Hypertrophic Scars: A Randomised Controlled Trial Comparing Chitosan Cream, Silicone Gel & Olive Oil
Hypertrophic Scars
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing AZX100 Drug Product in people with Scar Prevention and Scar Reduction, run by Capstone Therapeutics at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Oct 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Oct 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2012.